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Abstract: The risk of suicide in patients with epilepsy is significantly higher than the general 
population. There are many hypotheses as to the reasons for this, but the potential role of anti-
epileptic drugs (AEDs) in increasing suicidality has recently been brought into question. In 
2008, the U.S. Food and Drug Administration (FDA) published a warning after a meta-analysis 
of data from all clinical trials involving AEDs found a suicidality risk of 0.43 per 1000 patients 
in active drug arms of these clinical trials compared to a rate in the placebo arm of 0.22. While 
an increased risk for individual AEDs was found in two, the FDA decided to issue a warning for 
the entire AED class. While this decision and the meta-analysis findings have been considered 
controversial, and have created concern that this stated risk may dissuade use of AEDs by patients 
who would benefit from them, it has led to increased awareness of the risk of suicidality and 
psychiatric co-morbidity in this patient group. In this article, the association of epilepsy and 
AEDs with psychiatric disease and suicidality are reviewed, perspective as to the significance 
and limitations of the FDA’s findings are discussed, and some options for suicidality screening 
and their potential utility in clinical care are evaluated. 
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Suicide is a tragic outcome for patients with epilepsy given the therapeutic advances 
achieved in recent decades. Yet, suicide accounts for up to 11% of all deaths in epi-
lepsy patients, which is significantly higher than would be predicted by the United 
States general population suicide mortality rate of 1.4% and incidence rate of 11.6 per 
100,000 people.1–5 The rate of suicide as the cause of death in the epilepsy population 
varies widely, ranging from 0.7%–24% in the literature when limiting review to studies 
reporting a minimum of 100 deaths.2,3,6–10 The reasons for increased suicidality in the 
epilepsy population are likely numerous given its disruptive effect on socioeconomic 
factors, quality of life, and central nervous system physiology.11–15 However, some 
researchers have speculated whether antiepileptic drug (AED) treatment contributes 
to psychiatric comorbidity and suicidality in epilepsy.16,17 Indeed, negative quality of 
life factors and increased measures of distress have been identified in epilepsy patients 
on AED treatment, even in those with controlled seizures, which in some cases may 
prompt consideration of discontinuing therapy.12,18–20 The concern regarding the role 
played by AEDs in suicidality was recently heightened by the 2008 United States Food 
and Drug Administration (FDA) warning of an increased risk of suicidal behavior 
associated with the AED drug class based on a meta-analysis of all published AED 
clinical trials.21 This announcement prompted a renewed focus on the neuropsychiatric 
aspects of epilepsy, and raised new concerns about the safety profile of AED treatment. Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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In this review, we examine the association between AEDs and 
epilepsy with mental illness and suicidal behavior, and the 
data underlying the FDA warning. Screening tools available 
for clinical use in the evaluation of suicidality and depres-
sion are discussed. Finally, a perspective regarding the FDA 
findings as it relates to the management and counseling of 
AED therapy in epilepsy patients is provided.
Psychiatric and suicidal comorbidity 
in epilepsy: epidemiological 
considerations
epilepsy epidemiology and effects  
of treatment
The age-adjusted incidence of epilepsy in the Olmsted 
County population has been determined to be 44 per 100,000 
people, with a cumulative incidence of 3 per 100 through to 
the age of 75 years. The age-adjusted prevalence of active 
epilepsy is 6.8 per 1,000 people.22 Applied to an estimated US 
population of 350 million, this equates to 2.4 million patients 
in the US with epilepsy. AEDs are the mainstay of epilepsy 
treatment, and are   associated with a 60%–70% efficacy 
rate.23 Nonmedication   therapies include surgery, ketogenic 
diet, and neurostimulation   therapies. However, surgical treat-
ment is only appropriate for a select proportion of epilepsy 
patients and many epilepsy surgery patients still require AED 
therapy despite an excellent outcome. Currently available 
neurostimulation therapies in place and under development 
are palliative in most cases, and the ketogenic diet has not 
proven to be feasible for widespread use, at least in adult 
patients. Inadequate seizure control has been associated with 
injury, and injury can occur upon AED withdrawal even when 
performed in a controlled setting.24,25 In addition, poor seizure 
control has been shown to contribute to higher mortality in 
epilepsy, and is a consistent risk factor in sudden unexplained 
death in epilepsy patients (SUDEP).26,27 Thus, AEDs are a 
critical tool for clinicians in epilepsy management.
epilepsy and mental illness
Psychiatric comorbidity in epilepsy is well established. The 
prevalence of depression in epilepsy patients ranges from 
20%–55%28 and psychosis has been reported in 6%–9%.29 
These rates are significantly higher than those seen in the 
general population. Anxiety disorders and suicidal   ideation 
have also been found to be increased in patients with 
  epilepsy.30 However, not all psychiatric disorders have an 
overrepresentation in the epilepsy population, for example, 
bipolar affective disorder.31
Mental illness is likely underrecognized and undertreated 
in the epilepsy population. In some cases this results from 
an overlap between the symptoms and signs of both con-
ditions. During the typical office visit with the epilepsy 
patient, clinicians often focus on assessing seizure control 
and   determining medication adjustments, frequently at the 
expense of the evaluation of mental and psychosocial health. 
Neurology and epilepsy training programs lack emphasis on 
the evaluation and treatment of mental illness, contributing 
to an underrecognition of these disorders in this popula-
tion.32 In addition, some epilepsy patients may underreport 
or minimize symptoms of depression and anxiety. Epilepsy 
patients have variable and inconsistent access to psychiatric 
services, and those who do are often undertreated for fear of 
exacerbating seizure activity.28
Epilepsy appears to have a higher association with 
depression when compared to other chronic nonneurologic 
conditions.33 This epilepsy–depression association is cur-
rently thought to be secondary to a shared neurobiological 
basis as opposed to depression resulting from the psycho-
social limitations imposed by recurrent seizures. However, 
this subject remains controversial.28,34 Some investigators 
have shown a higher prevalence of depression with epilepsy 
compared to other chronic neurologic disorders, supporting 
the concept of seizures and epilepsy both arising from the 
same substrate of CNS dysfunction.35 However, others have 
not shown a difference in the rate of depression in epilepsy 
and other disabling noncentral nervous system (CNS) neu-
rological disorders.33
AeDs and mental illness
The possible role of AEDs in the development of depression 
in epilepsy has been the subject of controversy for many 
years. Some researchers have shown an association between 
mental illnesses and AED use.36 However, in many studies 
on this topic researchers have not been able to fully account 
for confounding factors such as preexisting psychiatric 
history and family history of mental illness.37,38 Some have 
shown incomplete seizure control to be associated with a 
higher rate of psychiatric comorbidity, arguing indirectly 
for a potential favorable role of AEDs if their use were to 
lead to maintenance of seizure freedom. Jacoby et al used 
the Hospital Anxiety and Depression Scale to demonstrate 
depression in 21% of 168 epilepsy patients.39 The depression 
rate in this study was shown to have the highest correlation 
with measures of current seizure activity. O’Donoghue et al 
compared the rates of depression and anxiety in epilepsy 
patients who were well-controlled and those with continuing Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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seizures. The rate of depression was 33% in patients with 
more than one seizure per month, 11% in those with less than 
one per month, and 6% in those controlled on medications.40 
However others have found evidence for psychopathology 
during periods of seizure control, raising concerns about the 
effects of “forced normalization”, in turn raising questions 
about whether there is always a direct relationship between 
seizure control and psychiatric status.41
epilepsy and suicide risk
The suicide rate in patients with epilepsy is higher than in 
the general population. The standardized mortality ratios 
(SMR) of suicide in epilepsy compared to the general 
population range from 3.5 to 5.8.42,43 Research evaluating the 
  proportionate mortality ratios (PMR) of suicide have shown 
suicide to account for 1% to 33% (mean = 11%) of all deaths 
in the epilepsy population, which is significantly higher than 
the 1.1%–1.2% rate in the general population.3 Even though 
many researchers have shown an increased suicide rate in 
the epilepsy population, in some population-based studies 
an increased incidence was not found.44,45 However, since 
accidental or seizure-related motor vehicle accidents, falls 
or drowning, and accidental overdose in epilepsy patients 
cannot always be distinguished from intentional events, it 
is possible that the epilepsy suicide rate documented in the 
literature is an underestimate.
Risk factors for suicide in epilepsy include age of 
seizure onset prior to age 18 years, the presence of preex-
isting mental illness, and co-treatment with antipsychotic 
therapy.46 Although suicide is more common in epilepsy in 
the setting of coexistent psychiatric illness,   epilepsy has 
also been found to be an independent risk factor for suicide, 
showing a calculated SMR of 1.99 in a group of epilepsy 
patients without presuicide evidence of mental illness.47 
In contrast to the general population, male gender is not a 
consistent risk factor in epilepsy suicidality.48,49   Polytherapy, 
poor seizure control, and seizure   localization or type have 
also not been determined to be consistent risk factors.3,46 
The duration of the epilepsy also does not directly cor-
relate with suicide risk; in fact, in one study, the highest 
suicide risk was observed in the first six months following 
  diagnosis.47 It is also important to note that suicide may 
occur as an   unpredictable acute phenomenon in association 
with   periictal psychosis.50 Interestingly, suicidality has also 
been implicated as a risk factor for the eventual develop-
ment of epilepsy, arguing again for the concept of mental 
illness and epilepsy both arising from a shared underlying 
neuropathologic substrate.51
AEDs and suicidality risk
In response to reported cases of suicidal behavior in patients 
taking AEDs, in 2005 the FDA ordered manufacturers of 
drugs classified as “anticonvulsants” to report all suicide-
related events in their controlled trial databases.52,53 This 
meta-analysis included data from 199 randomized clinical 
trials involving 11 anticonvulsant agents, and showed a near 
doubling of the risk of suicidal behavior compared to pla-
cebo when clinical trials for all indications were reviewed 
(odds ratio [OR], 1.8; 95% confidence interval [CI]: 1.2 
to 2.72). Data were available from over 27,800 patients 
receiving antiepileptic drugs and over 16,000 patients on 
placebo. Suicide behavior was defined as suicidal ideation, 
  preparatory acts, suicide attempts, and successful suicidal 
action. Suicide behavior occurred in 4.3 per 1,000 patients 
treated with antiepileptic drugs in the active arm compared 
with 2.2 per 1,000 patients in the placebo arm, leading to 
the public   statement that the suicidality rate was double that 
of   placebo.54 Of all the suicide behavior reported, suicidal 
  ideation accounted for 67.6%, preparatory acts for 2.8%, 
suicide attempts for 26.8%, and completed suicides in 
2.8%.55 This meta-analysis found four completed suicides 
in the active AED treatment arms of these studies and none 
in the placebo arms.56 Of the four people who successfully 
committed suicide, two were taking antiepileptic drugs 
for epilepsy, and two were in psychiatry clinical trials. 
There were 30 suicide attempts by patients taking active 
medication, and eight in the placebo arms. The suicide 
behavior risk was highest for those patients in epilepsy 
trials versus trials for other indications (OR, 3.5; 95% 
CI: 1.3 to 12.1).
The FDA issued a warning in January 2008, which can 
be accessed at: http://www.fda.gov/Drugs/DrugSafety/
PostMarketDrugSafetyInformationforPatientsandProviders/
ucm100200.htm, and a detailed report was subsequently pub-
lished.53 The lay press emphasized the FDA’s statement that 
anticonvulsants were associated with “about twice the risk of 
suicidal thoughts”, without specifying the absolute risk. Public 
attention to this was probably sensitized by the similarity of 
this report to warnings issued a few years previously regarding 
the increased risk of suicide in children associated with selec-
tive serotonin reuptake inhibitor (SSRI) use, and the two fold 
increased risk of vascular events associated with rofecoxib 
(Vioxx). The FDA’s initial response was to recommend a black 
box warning for the entire   anticonvulsant class, similar to that 
issued for SSRI’s.52   Subsequently, after much deliberation, a 
nonblack box warning was decided, and the FDA required 
manufacturers of drugs classified as anticonvulsants to prepare Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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a patient and provider guideline to assist in communicating 
this increased risk.
So, do antiepileptic drugs increase the suicide risk in 
a clinically significant manner? The absolute risk, though 
nearly double that in the placebo study arms, reflects an 
overall absolute suicidality rate of 0.43% compared to 0.22% 
with placebo, meaning that for every two patients with 
suicidal behavior associated with anticonvulsant use, 998 
patients would not. Similarly, it should be recognized that of 
the 27,863 patients enrolled in the active drug arm in these 
  studies, four actual suicides occurred and two of them were 
by patients in psychiatry trials. The high morbidity, mortality, 
and noncompliance rates inherent in the treatment of epilepsy 
have raised additional concerns that any such warning would 
dissuade some patients from taking medications in which 
they had a greater chance of helping their condition than of 
leading to suicide risk.
The FDA opinion was not embraced by practicing 
  epileptologists or the various professional societies devoted 
to treating patients with epilepsy.32 The American Epilepsy 
Society, the American Academy of Neurology, and the 
Epilepsy Foundation of America issued statements urging 
physicians and patients to exercise caution in interpreting the 
FDA ruling. The validity of the meta-analysis methodology 
used by the FDA in forming the basis of the recommendation 
was questioned.54,56 There were criticisms that the data on 
suicide behavior was not gathered in a systematic   prospective 
fashion, and that the presence of suicidality was gleaned 
from self-reported adverse events, the collection of which 
varied from site to site. Kanner and Hesdorffer argued that 
patients on active drugs tend to report more adverse events in 
general than those on placebo, stating that this   phenomenon 
may increase the chance of other negative symptoms being 
reported secondary to a “coat-tail effect”. The FDA has also 
been   criticized for using a portion of the 199   clinical tri-
als for the main statistical analysis which eliminated trials 
without suicide behavior in either arm. An ancillary analysis 
which included all events was performed but was criticized 
for the lack of calculation of a confidence interval. None of 
the patients in the felbamate clinical trials reported suicide 
behavior, and carbamazepine and valproate actually exhibited 
protective effects, yet these were included in the FDA AED 
class warning. Regarding the eight other AEDs included in 
the warning, only lamotrigine and topiramate individually 
reached statistical significance (see Table 1).53 Statistical 
analysis for heterogeneity across all trials did not produce 
significant results. Thus, the extrapolation of suicidality 
risk to the entire class of antiepileptic agents has been   
criticized.
The FDA approach in issuing a blanket warning 
encompassing all anticonvulsants is questionable. Despite 
the above points, the FDA ultimately decided to group all 
anticonvulsants as a class, and required the same warning 
for the whole AED class. This approach does not account 
for scientific data demonstrating different mechanisms of 
action for each AED.16 The FDA’s concern that specifi-
cally targeting drugs in this FDA warning would adversely 
prejudice clinical practices against the certain drugs runs 
counter to past FDA actions.54 The use of valproate in women 
of child-bearing age has decreased after data emerged of 
the drug’s potential for teratogenicity. Felbamate use has 
significantly decreased since the FDA published its black 
box warning linking the drug to increased risk for aplastic 
anemia and fatal hepatotoxicity. The rate of drug escalation 
for   lamotrigine was significantly reduced after data emerged 
that rapid dose escalation increased the risk for significant 
skin hypersensitivity reactions. Clinicians make therapeutic 
decisions daily regarding individual drugs based on that 
drug’s   pharmacologic characteristics and risk–benefit ratio. 
The approach of issuing a warning for the entire class has 
therefore been criticized.
Even while concern exists about the FDA’s approach to 
this issue, there is no disagreement that initiation of certain 
AEDs in patients with epilepsy may be associated with 
increased suicide risk. However, efforts to identify those 
AEDs with particular increased risk have shown inconsistent 
results. The ORs ratios of suicidal behavior and specific 
AEDs found in different studies are summarized in Table 1. 
In a Danish study in which pharmaceutical claims data were 
investigated revealed possible differences in suicide risk 
associated with different AEDs.57 The authors reported that 
AED initiation in general was associated with an increased 
risk of suicide (OR, 1.84; 95% CI: 1.36–2.49). In terms of 
the risk of specific AEDs, clonazepam (OR, 2.01; 95% CI: 
1.25–3.25), valproate (OR, 2.08; 95% CI: 1.04–4.16), lam-
otrigine (OR, 3.15; 95% CI: 1.35–7.34), and phenobarbital 
(OR, 1.96; 95% CI: 1.02–3.75) showed increased risk, while 
the remaining examined AEDs did not. The main weakness 
in this study was that it did not identify the clinical indication 
for AED use, and likely included patients treated with AEDs 
for mood and anxiety disorders, and chronic pain.
In an American cohort study the suicide rate in patients 
initiating AEDs prescription claims data in a health-system 
database over a 5-year period were investigated.58 Cox Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
185
Antiepileptic drugs and suicidality
proportional hazards models and   propensity score-matched 
analyses were used to   evaluate risk of attempted or com-
pleted suicide and combined   suicidal acts or violent death, 
controlling for psychiatric   comorbidities and other risk 
factors as determined by International Statistical Classifica-
tion of Diseases and Related Health Problems (ICD-9) and 
current procedural terminology codes. The suicidality rate 
of several   individual AEDs were   compared to the rate in 
patients taking   topiramate, and separately carbamazepine, 
as references. The researchers identified 26 completed 
suicides, 801 attempted suicides, and 41 violent deaths in 
297,620 patients initiating AED therapy. The incidence of 
the composite outcomes of completed suicides, attempted 
suicides, and violent deaths in patients receiving AEDs 
ranged from 6.2 per 1,000 person-years for primidone to 
34.3 per 1,000 person-years for oxcarbazepine. The risk of 
suicidal acts was increased for gabapentin (hazard ratio [HR], 
1.42; 95% CI: 1.11–1.80), lamotrigine (HR, 1.84; 95% CI: 
1.43–2.37), oxcarbazepine (HR, 2.07; 95% CI: 1.52–2.80), 
tiagabine (HR, 2.41; 95% CI: 1.65–3.52), and valproate 
(HR, 1.65; 95% CI: 1.25–2.19), compared with topiramate 
(see Table 1). As with the Danish study, these study results 
are confounded by the fact that all patients initiating AEDs 
were included, not just patients with epilepsy. The fact that 
gabapentin had the highest suicidality risk is important to 
note in this respect as it is chiefly used in the treatment of 
pain, as opposed to epilepsy.
Gibbons et al used the PharMetrics medical claims 
database to study the relationship between the 11 AEDs 
identified in the FDA alert, and lithium, to suicide attempts 
in a cohort of approximately 48,000 patients with bipolar 
affective   disorder.59   Suicide attempt rates were compared 
before and after   treatment and with a medication-free con-
trol group. Overall, there was no significant difference in 
suicide attempt rates for patients treated with an AED (13 
per 1,000   person-years [PY]) versus no AED or lithium 
treatment (13 per 1,000 PY). Of note, in patients treated with 
AEDs, the rate of suicide attempts was significantly higher 
before treatment (72 per 1,000 PY) than after (13 per 1,000 
PY). Also, in patients receiving no concomitant treatment 
Table 1 Studies in which suicidality potential of specific antiepileptic drugs (AEDs) was investigated 
Study Specific antiepileptic drugs and main published statistical findings 
FDA – Levenson 200853 Lamotrigine 2.08 (1.03–4.40)
N = 199 clinical trials  
involving AEDs
Topiramate 2.53 (1.21–5.85)
All other AeDs No significant risk
Oleson 201057 All AeDs at initiation 1.84 (1.36–2.49)
All patients prescribed Clonazepam 2.01 (1.25–3.25)
AEDs during study pd.,  
all diagnoses
valproate 2.08 (1.04–4.16)
Lamotrigine 3.15 (1.35–7.34)
Phenobarbital 1.96 (1.02–3.25)
Patorno 201058 Gabapentin 1.42 (1.11–1.80)
All patients initiated 
with AED therapy;  
using suicide rate with 
topiramate as reference
Lamotrigine 1.84 (1.43–2.37)
Oxcarbazepine 2.07 (1.56–2.80)
Tiagabine 2.41 (1.65–3.52)
valproate 1.65 (1.25–2.19)
Gibbons 201059 AeD therapy 13 suicides per 1000 pt-yrs
Bipolar affective  
disorder population
No AeD therapy 13 suicides per 1000 pt-yrs
No significant difference
van Cott 201060 Prior dx affective disorder 4.2 (2.4–7.5)
Suicide rates in all pts  
starting AED therapy,  
any indication vs epilepsy
AeD indication: epil vs other No significant difference
Lamotrigine & levetiracetam 10.2 (1.1–97.0)
valproate  2.3 (1.0–5.3)
Phenobarbital, phenytoin,
carbamazepine No significant difference
Andersohn 201061 “High” depressive potential* 3.08 (1.22–7.77)
Epilepsy cohort, those  
with suicidality vs no  
diagnosis of suicidality
“Low” depressive potential* 0.87 (0.47–1.59)
Conventional AeDs 0.74 (0.53–1.03)
Barbiturates 0.66 (0.25–1.73)
Notes: First author, abbreviated summary of study design, and main published statistical findings are shown. * = See text for definition of AEDs defined as having “high” and 
“low” depressive potential. Results displayed are Odd’s ratio + 95% confidence intervals except where otherwise indicated.Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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with an antidepressant, another AED, or antipsychotic, AEDs 
were shown to have a potential protective effect relative to 
no treatment (3 per 1,000 PY versus 15 per 1,000 PY). The 
weakness of this paper, vis-a-vis the context of the present 
discussion, is that it involved a nonepileptic cohort.
van Cott et al performed a case-control study of elderly 
American veterans starting AEDs for epilepsy compared 
to other diagnoses.60 Of the 112,096 patients (7,445 with 
new-onset epilepsy) who were on record as receiving AED 
monotherapy, 64 individuals had ICD-9 codes indicative of 
suicide-related behaviors. Rates of suicide-related behav-
iors were not significantly different for individuals taking 
AEDs for new-onset epilepsy compared to other diagnoses 
(P = 0.38). While in this study some of the questions raised by 
the FDA alert were directly examined, the outcome   measures 
were retrospectively measured using ICD-9 data, and not pro-
spectively performed. Of note, this study confirmed   previous 
reports of increased suicidality in epilepsy patients with a 
previous history of psychiatric disease.
The relative risk of different groups of AEDs for suicidal 
behavior or self-harm was evaluated using a case-control 
methodology utilizing data available in the United Kingdom 
General Practice Research Database.61 In this study, based 
on a cohort of 44,300 epilepsy patients, 453 cases with 
suicidal behavior or self-harm were matched with 8,962 
controls. AEDs were categorized into four subgroups: bar-
biturates, conventional AEDs, and newer AEDs with “low” 
or “high” potential for depression. The designation of “low” 
versus “high” potential for depression was based a priori on 
whether the frequencies of depressive symptoms in clinical 
trials of the specific drug in question were lesser or greater 
than 1%, respectively. The results showed AEDs with “high” 
depression potential (levetiracetam, tiagabine, topiramate, 
  vigabatrin) were associated with a threefold increased risk of 
self-harm or suicidal behavior (OR, 3.08; 95% CI: 1.22–7.77) 
compared to no AED use within the   previous year. The other 
three AED groups showed no increased risk. Analysis of 
individual AEDs showed an increase risk for levetiracetam 
only. In this study, polytherapy was not   associated with 
increased risk.
In summary, there are no prospective randomized con-
trolled studies in the literature to date addressing the ques-
tion of increased suicidality specifically in epileptic patients 
starting AEDs, or that allow consistent delineation of those 
AEDs at particular risk. A prospective study controlling for 
the many variables that affect suicidality is necessary to more 
securely implicate specific AEDs with suicide risk.
Suicide risk assessment  
and diagnostic tools
Depression, other mental illnesses, and suicidality are not 
consistently addressed or treated in the course of epilepsy 
care. In one survey of neurologists, 79% did not routinely 
screen for depression in epilepsy patients.28 In another 
performed after the FDA warning, 62% did not use any 
scale to routinely screen for depression in persons with 
epilepsy.32 Even for busy clinicians who do routinely assess 
for mood disorders, screening for suicide risk is challeng-
ing as the sensitivity and specificity of current office-based 
tools are suboptimal. In one study of 4,800 individuals 
  undergoing screening for suicidal ideation, 3.7% of 803 
identified as high risk completed suicide during a 5-year 
follow-up period, illustrating the nonspecificity of some 
screening tests for suicidal behavior.62 Furthermore, 37 of 
67 patients who   completed suicides were not identified 
as at risk by the screening techniques used in this study, 
illustrating the suboptimal sensitivity of these tools as   
well.
Several risk factors for suicide are worth keeping in 
mind when assessing patients. It is important to remember 
that the majority of patients who commit suicide have an 
Axis 1 psychiatric diagnosis. Also, those diagnoses of 
particular importance in the epilepsy population include 
major depressive disorder, anxiety disorder, and psychosis. 
For suicide in general, substance abuse is an important risk 
factor, as are the presence of a specific plan, ownership 
of a firearm, or access to other means of self-injury and 
death.5 Inquiry as to the presence of these risk factors may 
help in identifying patients at risk. A few researchers have 
suggested that the presence of postictal psychosis is a risk 
factor for suicide in epilepsy. Other risk factors identified in 
the epilepsy population include a positive family history of 
suicide, significant financial and family stress, and certain 
Axis II disorders such as antisocial and borderline personality   
disorder.3
Multiple suicide screening tools are available to clinicians, 
although none have proven to be clearly superior. Two com-
mon scales include the Mini-International Neuropsychiatric 
Interview (MINI) and SAD PERSONS scales.63,64 The Quality 
of Life In Epilepsy (QOLIE) survey also contains subques-
tions pertaining to suicidality, and can be used in the chronic 
care of epilepsy patients. Links to the various versions of 
the QOLIE can be found at http://www.rand.org/health/
surveys_tools/qolie/, and http://professionals.epilepsy.com/
page/qoltools.html. The QOLIE has not been validated for Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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use as a screening tool for suicidality; however, it can serve 
as an ongoing metric for monitoring mental health over time 
in epilepsy patients.
Many screening tools for depression are available for 
general clinical use and could be considered in the care of 
epilepsy patients. One of the most common is the PHQ-9.65 
In a meta-analysis review, the PHQ-9 was found to have 
a sensitivity of 81% and specificity of 92% for the detec-
tion of depression.66 The value of this tool in an individual 
patient is correlated to the a priori risk of depression in 
that patient. For example, if one assumes a 10% pretest 
probability of depression in a patient, the probability of 
depression is 53% with a positive screen, and 2.2% with a 
negative screen result. However, in a higher risk scenario 
with a 30% pretest probability of depression, the prob-
ability of depression with a positive screen is 81%, and 
8.1% with a negative result.65 The PHQ-9 takes less than 
3 minutes to perform.67 PHQ-9 results can be followed over 
time, and can also serve as a monitoring tool for long-term   
care.
Counseling epilepsy patients about 
the FDA AED suicidality warning
The FDA warning creates a quandary for physicians and 
patients. Physicians have expressed concern that the   warning 
may adversely affect medication compliance, leading to an 
increase in the morbidity, socioeconomic consequences, 
and potential mortality associated with uncontrolled sei-
zures.54 One might argue that the magnitude of the   absolute 
  suicidality risk was small and as such does not merit   emphasis 
in AED counseling. On the other hand, a   statistically signifi-
cant increase in suicidality risk was identified on review of 
aggregated data from clinical trials of 11 AEDs.   Therefore, 
the ethics of disclosure and consent can be argued to   suggest 
an obligation for the clinician to share these data when 
  counseling patients regarding AED   treatment.68 As an anal-
ogy, there is little controversy regarding the   advisability 
of counseling for other rare yet potentially serious AED 
complications such as Stevens–Johnson syndrome and 
lamotrigine,69   hepatotoxicity and valproate,70 and aplastic 
anemia, hepatoxicity, and felbamate.71 Thus, we advocate 
a balanced discussion with patients regarding the FDA 
report recommendations, as well as the benefits of seizure 
control and improved quality of life that AEDs can bring. 
Given the aforementioned shortcomings in the diagnosis 
of mental illness in epilepsy patients, clinicians should also 
consider ways to improve the detection of psychiatric ill-
ness in this population by judicious use of screening tools   
available.
Management recommendations  
for health care providers
The patient and family should be informed as to the gener-
ally increasing higher prevalence of psychiatric disorders 
in epilepsy, and educated as to the warning signs that may 
signal suicide risk. Patients can be reassured that although 
the rate of suicidal behavior was statistically increased with 
AED treatment versus placebo, the magnitude and rate 
was low, and for every suicide, there were 70 instances of 
nonfatal suicidality behaviors, which suggest the potential 
for prevention. Counseling regarding the consequences 
of nontreatment of epilepsy such as injury and SUDEP 
should be judiciously discussed in a patient leaning against 
therapy.72 Although data regarding death rates in untreated 
epilepsy patients are not directly available, the standard-
ized mortality rate associated with uncontrolled versus 
controlled epilepsy has been determined to range from   
1.6 to 9.3.10
As stated earlier, screening for mental illness and 
  suicidality is probably inadequate in the care of epilepsy 
patients,28 as in the primary care environment.73 In one study, 
45% of suicide victims had contact with their primary care 
providers within 1 month of their death.74 Since neurologists 
are often a primary physician contact for epilepsy patients, 
this emphasizes the importance of screening for mental illness 
and suicidality by epilepsy physicians. Inquiry regarding the 
presence of comorbidities that increase the risk of   suicidality 
should be performed in a consistent manner. Factors that 
increase suicide risk include alcohol and substance abuse, 
and concurrent psychiatric conditions such as depression, 
psychosis, and anxiety. In patients deemed to be at increased 
risk, it is appropriate to ask about a plan and whether they 
have access to a firearm or other methods of lethality. Urgent 
psychiatric assistance should be sought if significant risk is   
identified.
Finally, psychiatric services need to be routinely 
employed in the care of epilepsy patients when indicated. 
Although there is a small potential for seizure exacerbation 
associated with certain antidepressants, psychopharma-
cologic treatment can be successfully achieved without 
seizure   exacerbation and should not be withheld in patients 
when clinically indicated.9,75,76 Families should be made 
aware of the signs suggestive of suicidality, and encour-
aged to promptly notify their health care providers when Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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present so that proper evaluation and treatment can be   
initiated.
Conclusion
Mental illness is a significant comorbidity in epilepsy. Sui-
cidal behavior and successful suicides are increased in epi-
lepsy patients compared to the general population. The role 
that AEDs play in this comorbidity is at present unknown. 
What is known and generally accepted is that successful 
control of seizures is associated with improved quality of 
life, and lack of seizure control is associated with significant 
morbidity and in some cases death. The 2008 FDA warning 
that AEDs increase suicidal behavior has rekindled attention 
to this clinical problem.   Epileptologists and neurologists 
in general acknowledge that the use of some AEDs may 
infrequently be associated with an increased risk for suicidal 
behavior. However, many have criticized the FDA’s   decision 
to include all anticonvulsants in the warning, and some have 
questioned the validity of the meta-analysis methodology. 
Randomized controlled studies specifically addressing whether 
certain individual AEDs increase the incidence of psychiatric 
morbidity and suicidal behaviors are needed. In the absence 
of these data, we advocate routine screening of mood disor-
ders in the epilepsy patient and a balanced discussion of the 
potential benefits and side effects of AED therapy, including 
suicidal behavior.
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